Abstract
The irreversible human platelet aggregation induced by threshold concentrations of platelet-activating factor (PAF) in citrated plasma was reversed by aspirin (100 μmol/L, with 10 minutes' preincubation). The aspirin-sensitive amplification was linked to thromboxane generation, although thromboxane could be successfully replaced by cyclic endoperoxides, as suggested by the lack of effect of dazoxiben, a selective thromboxane-synthase inhibitor. The inhibitory effect of aspirin could be overcome by using 10 times higher PAF concentrations or, even more effectively, by combining threshold concentrations of both PAF and one of the other agonists studied (ADP, epinephrine, and U-46619, a stable endoperoxide analog, but not serotonin). The irreversible response obtained in both experimental conditions could also be made reversible by the use of BW 755C or nordihydroguaiaretic acid, inhibitors of both cyclooxygenase and lipoxygenase. It is concluded that the aspirin-sensitive pathway is sufficient but not necessary to amplify the primary response of human platelets to PAF. These data may be relevant to the current debate on the efficacy of aspirin in thrombosis prevention.
| Original language | English |
|---|---|
| Pages (from-to) | 653-658 |
| Number of pages | 6 |
| Journal | The Journal of Laboratory and Clinical Medicine |
| Volume | 105 |
| Issue number | 6 |
| Publication status | Published - 1985 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
- Pathology and Forensic Medicine
Cite this
Amplification of primary response of human platelets to platelet-activating factor : Aspirin-sensitive and aspirin-insensitive pathways. / Lauri, D.; Cerletti, C.; De Gaetano, G.
In: The Journal of Laboratory and Clinical Medicine, Vol. 105, No. 6, 1985, p. 653-658.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Amplification of primary response of human platelets to platelet-activating factor
T2 - Aspirin-sensitive and aspirin-insensitive pathways
AU - Lauri, D.
AU - Cerletti, C.
AU - De Gaetano, G.
PY - 1985
Y1 - 1985
N2 - The irreversible human platelet aggregation induced by threshold concentrations of platelet-activating factor (PAF) in citrated plasma was reversed by aspirin (100 μmol/L, with 10 minutes' preincubation). The aspirin-sensitive amplification was linked to thromboxane generation, although thromboxane could be successfully replaced by cyclic endoperoxides, as suggested by the lack of effect of dazoxiben, a selective thromboxane-synthase inhibitor. The inhibitory effect of aspirin could be overcome by using 10 times higher PAF concentrations or, even more effectively, by combining threshold concentrations of both PAF and one of the other agonists studied (ADP, epinephrine, and U-46619, a stable endoperoxide analog, but not serotonin). The irreversible response obtained in both experimental conditions could also be made reversible by the use of BW 755C or nordihydroguaiaretic acid, inhibitors of both cyclooxygenase and lipoxygenase. It is concluded that the aspirin-sensitive pathway is sufficient but not necessary to amplify the primary response of human platelets to PAF. These data may be relevant to the current debate on the efficacy of aspirin in thrombosis prevention.
AB - The irreversible human platelet aggregation induced by threshold concentrations of platelet-activating factor (PAF) in citrated plasma was reversed by aspirin (100 μmol/L, with 10 minutes' preincubation). The aspirin-sensitive amplification was linked to thromboxane generation, although thromboxane could be successfully replaced by cyclic endoperoxides, as suggested by the lack of effect of dazoxiben, a selective thromboxane-synthase inhibitor. The inhibitory effect of aspirin could be overcome by using 10 times higher PAF concentrations or, even more effectively, by combining threshold concentrations of both PAF and one of the other agonists studied (ADP, epinephrine, and U-46619, a stable endoperoxide analog, but not serotonin). The irreversible response obtained in both experimental conditions could also be made reversible by the use of BW 755C or nordihydroguaiaretic acid, inhibitors of both cyclooxygenase and lipoxygenase. It is concluded that the aspirin-sensitive pathway is sufficient but not necessary to amplify the primary response of human platelets to PAF. These data may be relevant to the current debate on the efficacy of aspirin in thrombosis prevention.
UR - http://www.scopus.com/inward/record.url?scp=0022218069&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022218069&partnerID=8YFLogxK
M3 - Article
C2 - 3923145
AN - SCOPUS:0022218069
VL - 105
SP - 653
EP - 658
JO - Journal of Laboratory and Clinical Medicine
JF - Journal of Laboratory and Clinical Medicine
SN - 0022-2143
IS - 6
ER -